Author:
Shirvani-Arani Simindokht,Ranjbar Hassan,Bahrami-Samani Ali
Abstract
AbstractThis study proposes the beta-emitting radioisotope 143Pr as a promising candidate for palliative treatment of metastatic bone pain due to its desirable physical decay characteristics. An optimized process was developed for the production and purification of non-carrier-added 143Pr using a medium flux research reactor. Calculations were performed to determine the optimal irradiation time and cooling period for irradiating 1 mg of natural cerium oxide to indirectly produce 143Pr through the decay of 143Ce. Following irradiation and cooling, extraction chromatography was employed to efficiently isolate 143Pr from the irradiated target material. A column containing Ln-resin was used along with nitric acid as the mobile phase and an optional oxidation step with NaBrO3/ascorbic acid to separate 143Pr from impurities such as 143Ce and 141Ce. Radionuclidic purity of over 99.995% was achieved as confirmed through gamma spectroscopy, demonstrating effective separation of 143Pr. Additional quality control analyses established the chemical and radiochemical purity of the purified 143Pr nitrate product. With a half-life of 13.6 days and maximum beta energy of 0.937 MeV, 143Pr exhibits favorable properties for palliative bone pain therapy. This study therefore provides a viable method for producing high-purity 143Pr through the optimized irradiation and purification processes described. Further investigation is warranted to explore potential clinical applications of 143Pr for palliation of metastatic bone cancer pain.
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Ayati, N. et al. Treatment efficacy of 153Sm-EDTMP for painful bone metastasis. Asia. Ocean. J. Nucl. Med. Biol. 1(1), 27–31 (2013).
2. Kraeber-Bodéré, F. et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur. J. Nucl. Med. 27, 1487–1493 (2000).
3. Fettich, J. et al. Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain: Results of an IAEA Coordinated Research Project. World J. Nucl. Med. 2(3), 226–231 (2003).
4. Solá, G. A. R. et al. Lutetium-177-EDTMP for bone pain palliation: Preparation, biodistribution and pre-clinical studies. Radiochim. Acta. 88(3–4), 157–161 (2009).
5. Nienke, J. M. et al. The various therapeutic applications of the medical isotope holmium-166: A narrative review. EJNMMI. Radiopharm. Chem. 4, 19 (2019).